After PV Progression, Which Patients Should Receive Second-Line Ruxolitinib vs Interferon (IFN)?
Dr. Srdan Verstovsek, MD Anderson Cancer Center, answers the following question: After PV progression, which patients should receive second-line ruxolitinib vs IFN?
Recent Video
Most Popular
Specialties :                    Search : is a member of the Oncology.TV family of oncology medical education websites. offers specialists, primary care physicians, and other healthcare professionals the timeliest comprehensive and relevant clinical information to improve patient care. We provide medical education (both free CE and non CE, including interactive case based presentations), news and information about Myeloproliferative Neoplasms (MPNs).